Advertisement

Topics

Combination Chemotherapy and Radiation Therapy in Treating Children With Acute Lymphoblastic Leukemia

2014-08-27 03:58:25 | BioPortfolio

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known which treatment regimen is more effective for acute lymphoblastic leukemia.

PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy and radiation therapy in treating children who have acute lymphoblastic leukemia.

Description

OBJECTIVES: I. Compare the efficacy and toxicity of doxorubicin with or without the cardioprotectant drug dexrazoxane in children with high risk acute lymphoblastic leukemia. II. Compare the efficacy and toxicity of hyperfractionated cranial radiation plus standard vs intensive intrathecal chemotherapy in preventing CNS leukemia in standard risk patients. III. Compare the efficacy and toxicity of hyperfractionated vs conventionally fractionated cranial radiation plus standard intrathecal chemotherapy in high risk patients. IV. Compare quality of life of these patients. V. Determine whether molecular evidence of leukemia is present in the bone marrow and peripheral blood at the time of remission induction and during intensification and continuation therapy and whether it disappears, changes over time, and is predictive of relapse.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to risk group (standard risk AND 2 to 8 years AND highest pretreatment WBC less than 20,000/mm3 vs all other standard risk vs high risk). The high risk stratum is further stratified according to dexrazoxane administration (yes vs no). Doxorubicin Investigational Window: Standard risk patients: Patients receive doxorubicin IV on days 0 and 1. High risk patients are randomized to one of two treatment arms: Arm I: Patients receive doxorubicin IV on days 0 and 1. Arm II: Patients receive dexrazoxane IV over 15 minutes immediately followed by doxorubicin IV on days 0 and 1. Induction Therapy for Patients Eligible for Investigational Window: Patients receive oral prednisone or prednisolone or methylprednisolone IV every 6 hours on days 2-30. Patients also receive vincristine IV on days 2, 9, 16, and 23; methotrexate IV over 1 hour on day 2; leucovorin calcium orally or IV every 6 hours beginning 36 hours after methotrexate; and E. coli asparaginase IM on day 4. Intrathecal methotrexate, cytarabine, and hydrocortisone are administered on days 16 and 30. Induction Therapy for Patients Ineligible for Investigational Window: Patients receive the same chemotherapy but at different timing intervals, which are determined by bilirubin levels. Patients who are in hematologic remission on day 30 proceed to CNS treatment. Patients who do not achieve remission by day 30 continue vincristine IV weekly for 3 weeks or until complete remission. Patients who do not achieve remission by day 51 are taken off study. Patients who are in hematologic remission but have CNS blasts on day 30 continue intrathecal chemotherapy, vincristine IV, and asparaginase IM weekly for 3 weeks (days 30, 37, and 44), and doxorubicin IV (with or without dexrazoxane, depending on earlier randomization) on day 30. Cranial radiation is delayed until CSF is clear. CNS Treatment for Standard Risk Patients: Patients receive chemotherapy consisting of vincristine IV for one dose and oral mercaptopurine for 14 days. Patients are then randomized to one of two treatment arms: Arm I: Patients undergo cranial radiotherapy twice a day for 10 days and receive intrathecal methotrexate and cytarabine twice weekly for 2 weeks. Arm II: Patients receive intrathecal methotrexate, cytarabine, and hydrocortisone twice weekly for 2 weeks. Girls with pretreatment WBC less than 20,000/mm3 are nonrandomly assigned to this arm. Patients who refuse randomization undergo conventional radiotherapy daily for 10 days plus receive intrathecal methotrexate and cytarabine twice weekly for 2 weeks. CNS Treatment for High Risk Patients At Least 365 Days Old: Patients receive the same chemotherapy regimen as standard risk patients, plus they receive intrathecal methotrexate and cytarabine twice weekly for 2 weeks. Patients receive doxorubicin with or without dexrazoxane as in the earlier randomization, then are randomized to one of two radiotherapy arms: Arm I: Patients undergo cranial radiotherapy daily for 10 days. Arm II: Patients undergo cranial radiotherapy twice daily for 10 days. Patients who refuse randomization receive therapy as in arm I. Intensification and Continuation Therapy for Patients At Least 365 Days Old: Therapy begins after CNS treatment and at least 3 weeks after complete remission is documented. Standard Risk: Patients receive vincristine IV every 3 weeks, oral prednisone or prednisolone twice a day for five days every 3 weeks, and oral mercaptopurine for 14 days every 3 weeks. E. coli asparaginase IM followed by methotrexate IV or IM are administered weekly for 18 weeks. Treatment is repeated as a 3 week sequence until continuous complete remission has been achieved for 24 months. Patients who had radiotherapy now receive intrathecal methotrexate and cytarabine every 18 weeks, while those patients who did not undergo radiotherapy receive intrathecal methotrexate, cytarabine, and hydrocortisone every 9 weeks for 6 doses, then every 18 weeks. High Risk: Patients receive vincristine, prednisone or prednisolone, mercaptopurine, asparaginase, and methotrexate as for standard risk patients. According to prior randomization, patients also receive doxorubicin IV every 3 weeks or dexrazoxane IV over 15 minutes and doxorubicin IV every 3 weeks. Doxorubicin is continued for 9 months or until the total cumulative dose is reached, then methotrexate IV is administered weekly. Treatment continues as for standard risk patients. Quality of life is assessed on induction day 23, during the second week of CNS therapy or at the start of intensification therapy, during the third week of intensification, during the first week of maintenance therapy (18 months after diagnosis), then every 2 years thereafter. Patients are followed every month for 6 months, every 2 months for 1 year, every 4 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 420 patients will be accrued for this study within 4 years.

Study Design

Allocation: Randomized, Primary Purpose: Treatment

Conditions

Cardiac Toxicity

Intervention

asparaginase, cytarabine, dexrazoxane hydrochloride, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, methylprednisolone, prednisolone, prednisone, therapeutic hydrocortisone, vincristine sulfate, quality-of-life assessment, ra

Location

Ochsner Clinic
New Orleans
Louisiana
United States
70121

Status

Active, not recruiting

Source

National Cancer Institute (NCI)

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:58:25-0400

Clinical Trials [3196 Associated Clinical Trials listed on BioPortfolio]

Pegasparaginase or Asparaginase and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving giving more than one ...

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: ...

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

This Phase II trial is studying how well giving epratuzumab together with an established chemotherapy platform works in treating young patients with relapsed acute lymphoblastic leukemia. ...

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: ...

Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor ce...

PubMed Articles [2378 Associated PubMed Articles listed on BioPortfolio]

Evidence for the involvement of TNF-α, IL-1β and IL-10 in the antinociceptive and anti-inflammatory effects of indole-3-guanylhydrazone hydrochloride, an aromatic aminoguanidine, in rodents.

Indole-3-guanylhydrazone hydrochloride (LQM01) is a new derivative of aminoguanidine hydrochloride, an aromatic aminoguanidine.

Association between total dose of ritodrine hydrochloride and pulmonary oedema in twin pregnancy: a retrospective cohort study in Japan.

Pulmonary oedema is recognised as a severe side effect of ritodrine hydrochloride. Recently, the number of twin pregnancies has been increasing. Few studies have reported the association between total...

Effect of Methamphetamine Hydrochloride on Pregnancy Outcome: A Systematic Review and Meta-analysis.

Methamphetamine hydrochloride is 1 of the most widespread psycho-stimulants in the world. Nevertheless, its effect on pregnant women and their neonates has not been investigated extensively.

Control of sheep gastrointestinal nematodes using the combination of Duddingtonia flagrans and Levamisole Hydrochloride 5.

The objective was to evaluate the action of D. flagrans pellets in association with Levamisole Hydrochloride 5% for controlling sheep gastrointestinal nematodes in the northeastern Brazil. Three group...

Neurotropic effect of B vitamins in the complex treatment of pain syndrome.

Combined vitamin preparations in therapeutic doses are used, along with simple analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle and epidural blockade, for the relief of acute pain. It...

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.

A naphthalene derivative and CALCIMIMETIC AGENT that increases the sensitivity of PARATHYROID GLAND calcium-sensing receptors to serum calcium. This action reduces parathyroid hormone secretion and decreases serum calcium in the treatment of PARATHYROID DISEASES.

A phenylethylamine derivative that acts as a calcium antagonist showing hemodynamic effects in patients with acute myocardial infarction.

The active metabolite of FOLIC ACID. Leucovorin is used principally as its calcium salt as an antidote to folic acid antagonists which block the conversion of folic acid to folinic acid.

A benzamide derivative that is used as a dopamine antagonist.

More From BioPortfolio on "Combination Chemotherapy and Radiation Therapy in Treating Children With Acute Lymphoblastic Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...


Searches Linking to this Trial